Electrophoresis Reagents Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Electrophoresis Reagents Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The electrophoresis reagents market is expected to register a CAGR of 5.11% during the forecast period.

Globally, the outbreak of COVID-19 was an incomparable public health emergency that affected almost every industry. The pandemic has had a positive impact on the market growth as electrophoresis techniques were used in the development of effective therapies to separate DNA, RNA, or protein molecules based on their size for effective therapies against COVID-19. For instance, as per the National Clinical Trial (NCT) Registry updated in July 2022, Elsan conducted a clinical trial to assess serum inflammation profiles by protein electrophoresis on patients hospitalized for infection due to the SARS-CoV-2 virus. Thus, increasing research and development activities in the development of effective therapies were expected to increase the demand for electrophoresis reagents during the COVID-19 pandemic. In addition, gel electrophoresis with other diagnostic technology was used in the detection of COVID-19. According to the study titled "High sensitivity-low cost detection of SARS-CoV-2 by two steps end point RT-PCR with agarose gel electrophoresis visualization" published in PubMed.gov in November 2021, the application of conventional PCR in conjunction with gel-electrophoresis for testing analysis is a possible approach for making SARS-CoV-2 diagnostics available worldwide. As a result, during the COVID-19 pandemic, the need for coronavirus disease diagnosis increased, and this trend is expected to continue during the projection period owing to the emergence of multiple variants, in turn propelling the market growth.

The major factors driving the electrophoresis reagents market include the increasing funding for genomic and proteomic research; the rising prevalence of chronic diseases; increasing collaborations between industry and academia; and technological developments. According to GLOBOCAN 2020, the new cancer cases that were diagnosed accounted for 19,292,789 in 2020 globally, with 9,958,133 deaths due to cancer. Among all cancers, breast cancer accounted for 2,261,419 new cancer cases, followed by lung cancer (2,206,771), prostate cancer (1,414,259), and colon cancer (1,148,515 new cases) in 2020. Additionally, as per the Global HIV and AIDS Statistics 2021 fact sheet by the Joint United Nations Program on HIV/AIDS (UNAIDS), 37.7 million people globally were living with HIV in 2020, and 1.5 million people became newly infected with HIV in 2020. As the prevalence of diseases increases, researchers continue to focus on providing prospective treatment options through research & development, which raises the need for gel electrophoresis and, ultimately, electrophoresis reagents, consequently promoting the market’s growth.

Furthermore, increased research funding and ongoing initiatives by research institutes and key players in the industry generate demand in the studied market. For instance, in December 2020, the United Kingdom Biobank collaborated with the Biopharma Consortium, comprising ten biopharmaceutical companies, on the Pharma Proteomics Project, for a better understanding of disease processes and to support innovative drug development. Additionally, technological advancement in electrophoresis instruments further propels the growth of the market. For instance, in September 2021, a novel capillary electrophoresis system, BioPhase8800, was introduced by Sciex Company for biological characterization during biopharmaceutical therapy. The new device analyzes eight samples simultaneously and is a multi-capillary system for capillary electrophoresis sodium dodecyl sulfate (CE-SDS).

Therefore, factors like increasing funding for genomic and proteomic research, the rising prevalence of chronic diseases, and technological developments are expected to promote the growth of the electrophoresis reagents market over the forecast period. However, time-consuming operations and the availability of other alternatives may restrain the market's growth over the forecast period.

Key Market TrendsGel Electrophoresis Segment is Expected to Hold a Major Market Share

The major factors driving the gel electrophoresis segment include low operating and instrument costs, rising applications in the pharmaceutical and biotechnology industries, and the increasing burden of infectious diseases, cancer, and genetic disorders.

According to the study published in the PLOS ONE Journal in May 2022, titled "Application of two-dimensional difference gel electrophoresis to identify protein changes between center, margin, and adjacent non-tumor tissues obtained from non-small-cell lung cancer with adenocarcinoma or squamous cell carcinoma subtype" a gel electrophoresis technique was used to identify many proteins that are significant for improved characterization of tumor progression and molecular specificity of both lung cancer subtypes. As a result of gel electrophoresis, it is possible to distinguish proteins from tumor cells, which aids in tumor diagnosis and may contribute to the segment's growth.

The growing technological advancement and product launches by the market players are expected to boost the market segment’s growth further. For instance, in September 2020, miniPCR bio launched GELATO, a gel electrophoresis system with an integrated blue light with transillumination technology, allowing simultaneous nucleic acid separation.

Hence, owing to the above factors, the segment is expected to grow in the coming years.

North America Holds the Largest Market Share in the Electrophoresis Reagents Market

The major factors driving the market growth in North America include the increasing number of genomic research projects; the growing prevalence of chronic diseases; collaborations between industry and academia; cumulative research and development expenditure; the presence of a large number of major players; product launches; and technological advancements. The prevalence of cancer and infectious diseases is expected to drive market growth. For instance, according to GLOBOCAN 2020, the total number of new cancer cases was 2,281,658 in the United States. The most common cancers in the United States were breast cancer, lung cancer, prostate cancer, colorectum cancer, bladder cancer, and skin cancer. Additionally, in September 2020, Hitachi High-Tech Corporation, based in Japan, launched a Hitachi DS3000 compact capillary electrophoresis (CE) sequencer in collaboration with Promega Corporation, based in the United States. The Hitachi DS3000 is an easy-to-use, portable CE sequencer that can be used for verifying significant amounts of gene-sequence data that have been analyzed by next-generation sequencers and carrying out fragment analysis used in human identification. It is anticipated that it will be adopted in locations like university core facilities and small-scale research laboratories. Such collaboration between the companies is expected to boost the market in the region over the coming years.

Growth in R&D investment by the pharmaceutical and biopharmaceutical industries related to life science tools, research, and academics is expected to drive the market. For example, according to the Pharmaceutical Research and Manufacturers of America (PhRMA), the United States biopharmaceutical industry is one of the world's leaders in new drug development. The entire biopharmaceutical and pharmaceutical industry invested an estimated USD 91.1 billion in research and development (R&D) in 2020, compared to about USD 83 billion invested in research and development (R&D) in 2019. As a result of increased research and development spending, it is projected that research and development activity will expand, driving demand for electrophoresis reagents and promoting the market's growth.

Thus, these factors altogether contribute to regional growth.

Competitive Landscape

The electrophoresis reagents market is moderately fragmented and competitive. The major players are found to adopt various strategies, such as agreements, expansion, contracts, partnerships, new reagent developments, joint ventures, and mergers and acquisitions, to strengthen their positions in the market. Some of the companies currently dominating the market are Agilent Technologies Inc., BioAtlas, Bio-Rad Laboratories Inc., Cytiva, Lonza Group AG, Merck KGaA, Qiagen NV, Sigma-Aldrich Corporation, Takara Bio Inc., and Thermo Fisher Scientific, among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.